C2 CryoBalloon
Device
PENTAX of America, Inc.
Total Payments
$1.4M
Transactions
476
Doctors
234
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $507,373 | 15 | 0 |
| 2023 | $446,647 | 98 | 56 |
| 2022 | $153,613 | 200 | 135 |
| 2021 | $210,839 | 75 | 44 |
| 2017 | $99,966 | 88 | 44 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.2M | 85 | 88.1% |
| Consulting Fee | $59,471 | 11 | 4.2% |
| Honoraria | $42,700 | 15 | 3.0% |
| Travel and Lodging | $38,964 | 51 | 2.7% |
| Food and Beverage | $18,485 | 311 | 1.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,400 | 2 | 0.5% |
| Space rental or facility fees (teaching hospital only) | $2,000 | 1 | 0.1% |
Payments by Type
Research
$1.2M
85 transactions
General
$169,020
391 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Multi-center Clinical Study to Evaluate the C2 CryoBalloon Focal Ablation System for the Treatment of Patients With Previously Untreated Dysplastic Barrett's Epithelium | PENTAX of America, Inc. | $676,687 | 0 |
| Coldplay 3: Multi-Center Clinical Study to Evaluate the Coldplay CryoBalloonTM Focal Ablation System for the Treatment of Patients with Previously- Untreated Dysplastic Barrett's Epithelium | PENTAX of America, Inc. | $264,732 | 0 |
| Nitrous Oxide CryoBalloon Ablation forEradication of Non-Ampullary Sporadic and Familial Duodenal Adenomas | PENTAX of America, Inc. | $83,793 | 0 |
| Coldplay 3 | PENTAX of America, Inc. | $62,510 | 0 |
| Coldplay 3: Multicenter Clinical Study to Evaluate the C2 CryoBalloon Focal Ablation System for the Treatment of Patients with Previously Untreated Dysplastic Barrett's Epithelium | PENTAX of America, Inc. | $29,234 | 0 |
| Evaluation of CryoBalloon Focal Ablation System in patients with Barrett's Esophagus (Coldplay 2) | PENTAX of America, Inc. | $26,390 | 0 |
| Nitrous Oxide for Endoscopic Ablation of Refractory Barrett's Esophagus | PENTAX of America, Inc. | $22,934 | 0 |
| 522 Study Site - Admin Start Up Fee | PENTAX of America, Inc. | $20,400 | 0 |
| CryoBalloon Ablation for Treatment of Duodenal Adenomas (C2D2) | PENTAX of America, Inc. | $16,990 | 0 |
| Multi-Center Clinical Study to Evaluate the Coldplay CryoBalloonTM Focal Ablation System for the Treatment of Patients with Previously Untreated Dysplastic Barretts Epithelium (Coldplay 3) | PENTAX of America, Inc. | $12,660 | 0 |
| 522 Postmarket Surveillance Study | PENTAX of America, Inc. | $12,600 | 0 |
| Coldplay III | C2 Therapeutics, Inc | $5,288 | 2 |
| Safety and Efficacy of the Cryoballoon Ablation for the treatment of Sporadic and Familial Nonampullary Nonpolypoid Duodenal Adenomas: C2D2 trial | PENTAX of America, Inc. | $5,120 | 0 |
| Safety and Efficacy of the Cryoballoon Ablation for treatment of Sporadic and Familial Nonampullary Nonpolypoid Duodenal Adenomas | PENTAX of America, Inc. | $5,080 | 0 |
| Multi-Center Clinical Study to Evaluate the Coldplay CryoballoonTM Focal Ablation System for the Treatment of Patients with Previously Untreated Dysplastic Barrett's Epithelium (COLDPLAY 3) | PENTAX of America, Inc. | $5,000 | 0 |
Top Doctors Receiving Payments for C2 CryoBalloon
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Pittsburgh, PA | $1.2M | 84 |
| George Triadafilopoulos | — | Mountain View, CA | $43,600 | 4 |
| , M.D | Student in an Organized Health Care Education/Training Program | Danville, PA | $22,153 | 18 |
| , M.D | Gastroenterology | Danville, PA | $12,741 | 8 |
| , MD | Gastroenterology | New Hyde Park, NY | $9,824 | 7 |
| , MD | Gastroenterology | New York, NY | $9,567 | 5 |
| , M.D | Gastroenterology | New York, NY | $6,978 | 4 |
| , MD | Gastroenterology | Orange, CA | $6,492 | 6 |
| , M.D | Internal Medicine | Washington, DC | $5,925 | 6 |
| , M.D | Gastroenterology | Rochester, MN | $5,208 | 4 |
| , MD | Gastroenterology | Chapel Hill, NC | $4,439 | 3 |
| , M.D | Gastroenterology | Baltimore, MD | $3,234 | 5 |
| , MD | Gastroenterology | Baltimore, MD | $1,844 | 3 |
| , MD | Internal Medicine | San Francisco, CA | $1,707 | 1 |
| Vanessa Shami | Gastroenterology | Charlottesville, VA | $1,621 | 3 |
| , M.D | Gastroenterology | Charleston, SC | $1,537 | 1 |
| , MD | Gastroenterology | New Hyde Park, NY | $1,500 | 1 |
| , MD | Gastroenterology | Kenner, LA | $1,496 | 10 |
| , MD | Gastroenterology | Cleveland, OH | $1,444 | 2 |
| , M.D | Gastroenterology | Dallas, TX | $1,368 | 3 |
| , M.D | Gastroenterology | Baltimore, MD | $1,340 | 5 |
| , M.D | Internal Medicine | Sarasota, FL | $1,113 | 1 |
| , M.D | Gastroenterology | Orange, CA | $1,074 | 2 |
| , M.D | Gastroenterology | Boston, MA | $983.41 | 2 |
| , M.D | Gastroenterology | New York, NY | $915.94 | 1 |
Ad
Manufacturing Companies
- PENTAX of America, Inc. $1.3M
- C2 Therapeutics, Inc $99,966
Product Information
- Type Device
- Total Payments $1.4M
- Total Doctors 234
- Transactions 476
About C2 CryoBalloon
C2 CryoBalloon is a device associated with $1.4M in payments to 234 healthcare providers, recorded across 476 transactions in the CMS Open Payments database. The primary manufacturer is PENTAX of America, Inc..
Payment data is available from 2017 to 2024. In 2024, $507,373 was paid across 15 transactions to 0 doctors.
The most common payment nature for C2 CryoBalloon is "Unspecified" ($1.2M, 88.1% of total).
C2 CryoBalloon is associated with 15 research studies, including "Multi-center Clinical Study to Evaluate the C2 CryoBalloon Focal Ablation System for the Treatment of Patients With Previously Untreated Dysplastic Barrett's Epithelium" ($676,687).